TSE:6613 stock news
This page provides real-time market news, earnings updates, and company announcements related to QD Laser, Inc. (TSE:6613).
All content is aggregated from trusted financial media and market data sources to help investors stay informed about key market movements and corporate developments.
Last updated as of 2026-04-17 19:38 JST
Erasca Announces Issuance of a U.S. Patent Covering Pan-KRAS Inhibitor ERAS-4001
Finviz2026-02-24 13:03:11
Erasca and Tango Therapeutics Enter into Clinical Collaboration to Evaluate Combination of ERAS-0015 and Vopimetostat
Finviz2026-03-05 12:06:05
Immuneering Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
Finviz2026-03-06 12:46:17
Mineralys Therapeutics Announces FDA Acceptance of NDA for Lorundrostat for Treatment of Adults with Hypertension and Topline Explore-OSA Trial Results
Finviz2026-03-09 20:40:44
Erasca Exercises Option to Secure Worldwide Rights for ERAS-0015 Pan-RAS Molecular Glue to Include China, Hong Kong, and Macau
Finviz2026-03-10 12:03:12
Erasca Reports Fourth Quarter and Full Year 2025 Business Updates and Financial Results
Finviz2026-03-12 20:06:49
Biomea Fusion Presents Phase II COVALENT-111 Data in Type 2 Diabetes at the 19th International Conference on Advanced Technologies & Treatments for Diabetes 2026
Finviz2026-03-14 08:33:49
Merck to Acquire Terns Pharmaceuticals, Inc., Expanding Its Hematology Pipeline With TERN-701, a Novel Candidate for Chronic Myeloid Leukemia (CML)
Finviz2026-03-25 10:51:46
Zentalis Pharmaceuticals Reports Full Year 2025 Financial Results and Operational Updates
Finviz2026-03-26 20:09:54
ORIC Pharmaceuticals Reports Selection of Rinzimetostat RP3D in Combination with Darolutamide for Himalayas-1 Phase 3 Global Study with Dose Optimization Data Supporting Its Potential Best-in-Disease Profile
Finviz2026-03-31 20:09:08
Zentalis Pharmaceuticals Announces 400mg QD 5:2 Azenosertib Monotherapy as the Pivotal Study Dose in Cyclin E1-Positive Platinum-Resistant Ovarian Cancer
Finviz2026-04-09 12:03:53
Corbus Pharmaceuticals Announces Last Patient First Visit in CANYON-1 Study of CRB-913 for the Treatment for Obesity
Finviz2026-04-14 12:06:47
Aligos Therapeutics Announces First Interim Analysis Results from the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium in Participants with Chronic Hepatitis B Virus Infection and Grant of FDA Fast Track Designation
Finviz2026-04-14 20:06:56
Erasca Exercises Option to Secure Worldwide Rights for ERAS-0015 Pan-RAS Molecular Glue to Include China, Hong Kong, and Macau
Finviz2026-03-10 12:03:12
Erasca Reports Fourth Quarter and Full Year 2025 Business Updates and Financial Results
Finviz2026-03-12 20:06:49
Biomea Fusion Presents Phase II COVALENT-111 Data in Type 2 Diabetes at the 19th International Conference on Advanced Technologies & Treatments for Diabetes 2026
Finviz2026-03-14 08:33:49
Merck to Acquire Terns Pharmaceuticals, Inc., Expanding Its Hematology Pipeline With TERN-701, a Novel Candidate for Chronic Myeloid Leukemia (CML)
Finviz2026-03-25 10:51:46
Zentalis Pharmaceuticals Reports Full Year 2025 Financial Results and Operational Updates
Finviz2026-03-26 20:09:54
ORIC Pharmaceuticals Reports Selection of Rinzimetostat RP3D in Combination with Darolutamide for Himalayas-1 Phase 3 Global Study with Dose Optimization Data Supporting Its Potential Best-in-Disease Profile
Finviz2026-03-31 20:09:08
Zentalis Pharmaceuticals Announces 400mg QD 5:2 Azenosertib Monotherapy as the Pivotal Study Dose in Cyclin E1-Positive Platinum-Resistant Ovarian Cancer
Finviz2026-04-09 12:03:53
Corbus Pharmaceuticals Announces Last Patient First Visit in CANYON-1 Study of CRB-913 for the Treatment for Obesity
Finviz2026-04-14 12:06:47
Aligos Therapeutics Announces First Interim Analysis Results from the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium in Participants with Chronic Hepatitis B Virus Infection and Grant of FDA Fast Track Designation
Finviz2026-04-14 20:06:56
TSE:6613 stock price change
On the last trading day, TSE:6613 stock closed at 1381.00 JPY, with a price change of 3.21% for the day.
Trade stock perpsTSE:6613 stock detailsAbout Bitget
The world's first Universal Exchange (UEX), enabling users to trade not only cryptocurrencies, but also stocks, ETFs, forex, gold, and real-world assets (RWA).
Learn more